The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global radiation oncology market reached a value of US$ 6.97 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 10.88 Billion by 2027, exhibiting a CAGR of 7.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Radiation oncology, also known as radiotherapy, is a cancer treatment that relies on high doses of radiation to kill cancer cells and shrink tumors. It is considered a localized treatment as it affects only the part of the body being treated and damages cancer cells without harming healthy cells. It can be delivered via machines called linear accelerators or through radioactive sources placed inside the patient on a temporary or permanent basis.
The increasing risk of developing cancer on account of tobacco and alcohol consumption, unhealthy diet and physical inactivity among individuals represents one of the key factors bolstering the growth of the market. Besides this, there is a rise in the adoption of radio oncology, which includes external beam radiation therapy, to treat breast, colorectal, esophageal, head, neck, lung, and prostate cancer. It also comprises radioactive iodine therapy (I-131), which can cure a few thyroid cancers, and targeted radionuclide therapy that helps treat advanced prostate cancer or gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Moreover, palliative radiation aids in relieving difficulties like pain, trouble swallowing or breathing, or bowel blockages caused by advanced cancer. This, coupled with the rapid expansion of cancer research centers around the world, is positively influencing the market. Furthermore, key players are focusing on motion tracking, real-time imaging and advancements from 2D to 3D conformal radiotherapy. They are also integrating artificial intelligence (AI) to improve the accuracy, precision, efficiency, and overall effectiveness of radiation oncology. This, in confluence with the increasing investments in research and development (R&D) activities by governments of numerous countries, is projected to fuel the growth of the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global radiation oncology market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, technology, application and end user.
Breakup by Type:
Breakup by Technology:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accuray Incorporated, Becton Dickinson and Company, Canon Inc., Elekta, Hitachi Ltd., Icad Inc., Ion Beam Applications, Isoray Inc., Mevion Medical Systems Inc., Nordion (Canada) Inc. (Sotera Health), P-Cure Ltd., Varian Medical Systems Inc. (Siemens Healthineers AG) and ViewRay.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Technology, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Accuray Incorporated, Becton Dickinson and Company, Canon Inc., Elekta, Hitachi Ltd., Icad Inc., Ion Beam Applications, Isoray Inc., Mevion Medical Systems Inc., Nordion (Canada) Inc. (Sotera Health), P-Cure Ltd., Varian Medical Systems Inc. (Siemens Healthineers AG) and ViewRay.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at